News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
177,073 Results
Type
Article (17146)
Company Profile (124)
Press Release (159803)
Section
Business (57925)
Career Advice (919)
Deals (9308)
Drug Delivery (30)
Drug Development (23249)
Employer Resources (70)
FDA (2291)
Job Trends (4195)
News (91636)
Policy (5761)
Tag
Academia (478)
Africa (322)
Alliances (16081)
Alzheimer's disease (335)
Antibody-drug conjugate (ADC) (39)
Approvals (2253)
Arizona (23)
Artificial intelligence (36)
Asia (13137)
Australia (2593)
Bankruptcy (75)
Best Places to Work (2779)
Biotechnology (112)
C2C Services and Suppliers (7903)
California (734)
Canada (333)
Cancer (194)
Career advice (740)
CAR-T (35)
Cell therapy (78)
China (56)
Clinical research (17638)
Collaboration (85)
Connecticut (28)
COVID-19 (710)
Cystic fibrosis (26)
Data (99)
Diagnostics (998)
Diversity, equity & inclusion (21)
Earnings (15222)
Employer resources (67)
Europe (29238)
Events (29933)
Executive appointments (85)
FDA (2334)
Florida (69)
Funding (75)
Gene editing (21)
Gene therapy (56)
GLP-1 (213)
Government (586)
Healthcare (2338)
Hotbed/Location (113636)
Illinois (71)
Indiana (44)
Infectious disease (718)
Inflammatory bowel disease (43)
Interviews (132)
IPO (4012)
Job creations (1466)
Job search strategy (695)
Layoffs (120)
Legal (1167)
Lung cancer (37)
Management (21)
Manufacturing (42)
Maryland (119)
Massachusetts (555)
Medical device (666)
Medtech (667)
Mergers & acquisitions (5281)
Metabolic disorders (86)
Michigan (43)
Minnesota (76)
Neuroscience (407)
New Jersey (214)
New York (190)
NextGen Class of 2024 (1422)
Non-profit (448)
North Carolina (199)
Northern California (302)
Obesity (47)
Ohio (30)
Opinion (157)
Patents (32)
Pennsylvania (193)
People (21465)
Phase I (6844)
Phase II (8416)
Phase III (4777)
Pipeline (42)
Policy (28)
Postmarket research (298)
Preclinical (2781)
Press Release (61)
Rare diseases (61)
Real estate (2425)
Recruiting (35)
Regulatory (4228)
Research institute (514)
Resumes & cover letters (147)
Series A (24)
South America (395)
Southern California (314)
Startups (1772)
Texas (56)
United States (2895)
Vaccines (139)
Washington State (174)
Weight loss (51)
Date
Today (38)
Last 7 days (223)
Last 30 days (866)
Last 365 days (12922)
2024 (9266)
2023 (13203)
2022 (16046)
2021 (16934)
2020 (13186)
2019 (9502)
2018 (7543)
2017 (8982)
2016 (8121)
2015 (9410)
2014 (9727)
2013 (9450)
2012 (6091)
2011 (6471)
2010 (5843)
177,073 Results for "fortress biotech".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2024.
May 15, 2024
·
15 min read
Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
Fortress Biotech, Inc. today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company.
May 16, 2024
·
1 min read
Business
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.
March 28, 2024
·
14 min read
Drug Development
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation
Fortress Biotech, Inc. today announced that the first patient was dosed in a multi-center, placebo-controlled, randomized Phase 2 study of Triplex, a vaccine for control of cytomegalovirus (“CMV”), in patients undergoing liver transplantation.
May 14, 2024
·
9 min read
Press Releases
Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 4, 2024
·
1 min read
Fortress Biotech to Participate in 36th Annual ROTH Conference
Fortress Biotech, Inc. today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the 36th Annual ROTH Conference on Monday, March 18, 2024, at 2:00 p.m. PT.
March 12, 2024
·
1 min read
Press Releases
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
August 14, 2024
·
17 min read
BioMidwest
Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Fortress Biotech, Inc. announced the closing of its previously announced registered direct offering.
January 3, 2024
·
5 min read
Press Releases
Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027
July 25, 2024
·
6 min read
Business
Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
July 8, 2024
·
5 min read
1 of 17,708
Next